Paroxysmal Kinesigenic Dyskinesia Symptoms Markedly Reduced with Parenteral Vitamins and Minerals: A Case Report

Tweet

Alisha Bruton^1,2,3; Leslie Fuller, ND^2,4

Perm J 2019;23:19.036 [Full Citation]

https://doi.org/10.7812/TPP/19.036

E-pub: 10/03/2019

ABSTRACT

Introduction: Paroxysmal kinesigenic dyskinesia (PKD) is a rare movement disorder triggered by sudden voluntary movements. The disorder involves attacks of chorea, which resolve within minutes, that may occur frequently throughout the day.
Case Presentation: A 61-year-old woman presented to the clinic with a 13-year history of PKD first diagnosed in 2002. This patient had frequent episodic attacks of PKD, which were so severe she had difficulty with ambulation and other activities of daily living. The case was complicated by an additional diagnosis of chronic fatigue syndrome. She refused antiseizure medication because of concerns about it exacerbating her fatigue. In the office, she was given weekly parenteral doses of vitamins and minerals, which almost completely eliminated her symptoms between treatments and allowed her to return to activities of daily living.
Discussion: Genetic testing, not related to her PKD diagnosis, revealed several mutations that could offer an explanation for the apparent efficacy of parenteral therapy in this patient.

INTRODUCTION

The paroxysmal dyskinesias are a group of rare disorders characterized by attacks of involuntary movements that resolve quickly.¹ Paroxysmal kinesigenic dyskinesia (PKD) is the most common type of paroxysmal dyskinesia and is triggered by sudden voluntary movements.² PKD can be inherited, acquired, or caused by another neurologic disorder.¹ Attacks of PKD can occur multiple times per day and have many triggers. The frequency of attacks ranges from once a year to hundreds of time per day. Common triggers include voluntary movements such as getting in and out of a car or moving from sitting to standing.³ 

Dyskinesias are commonly diagnosed from a clinical history, as most patients have normal neurologic findings between attacks.¹ Although the etiology of primary PKD is not fully understood, the disorder responds to treatment with levodopa, flunarizine, and tetrabenazine, suggesting that hyperexcitability in the basal ganglia may play a role.⁴ Other treatment options include anticholinergic agents or antiseizure medication.⁵ Genetic studies have revealed that autosomal-dominant mutations in the PRRT2 gene (proline-rich transmembrane protein 2) may be responsible for some cases of inherited PKD. PRRT2 acts to inhibit vesicular release of neurotransmitters, and its gene mutation may lead to excess neurotransmitter release into the synapse.^2,6 PRRT2 inhibits the release of multiple neurotransmitters, perhaps explaining why PKD can respond to many classes of medications, including dopamine precursors, sodium channel blockers, and calcium channel blockers.

To the best of our knowledge, this is the first case report examining PKD treated successfully with parenteral vitamin and mineral therapy. This case report was written following the CARE (CAse REport) guidelines.⁷ 

CASE PRESENTATION

Presenting Concerns

A 61-year-old woman presented to the clinic with PKD, which was so severe she was not ambulatory and had difficulty with activities of daily living. Thirteen years earlier, in 2002, she had experienced her first attack, after which she was evaluated in the hospital, where stroke and myocardial infarct were ruled out. Brain magnetic resonance imaging findings were normal, and although multiple laboratory tests were done (antinuclear antibodies, lupus anticoagulant panel, vitamin B₂ glycoprotein, and cardiolipin antibodies), the results were remarkable only for increased high-sensitivity C-reactive protein and erythrocyte sedimentation rate. Later that year, she received the diagnosis of PKD from a neurologist on the basis of her symptoms and history. Genetic testing consistent with the clinical diagnosis of PKD was not available in 2002.

The patient had a previous diagnosis of chronic fatigue syndrome/myalgic encephalomyelitis. She had no family history of PKD, chorea, Parkinson disease, multiple sclerosis, tremors, seizure disorders, or stroke. Her family history did include systemic lupus erythematosis. For 13 years, she had repeated daily episodes of PKD that incapacitated her, limiting her ability to perform activities of daily living and causing her to be nonambulatory. The neurologist managing her case offered her antiseizure medication to manage the PKD symptoms, but she refused because of concerns about exacerbation of her fatigue caused by chronic fatigue syndrome.

Previous genetic testing, before this episode of care, revealed the patient was homozygous for the C variant of the NBPF3 gene, which is associated with low absorption and use of pyridoxine (vitamin B₆). She also was heterozygous for both the A1298C and the C677T MTHFR mutations, suggesting a reduced ability to convert precursors into active folate (vitamin B₉). Additionally, she was homozygous for the glutamate decarboxylase-1 (GAD1) mutation, which could interfere with conversion of g-aminobutyric acid from glutamate.

Therapeutic Intervention and Treatment

In 2015, the patient presented to the clinic requesting parenteral therapy with vitamins and minerals to address her episodes of dyskinesia. The patient had an episode in the office in which she experienced dyskinesia that interfered with her ability to move and speak. She was treated at this first office visit (Table 1) and reported immediate symptom relief. At a second office visit 1 week later, she reported that after treatment, she had experienced her first entirely symptom-free period since the onset of her symptoms 13 years earlier. She was able to undertake activities of daily living and reported increased energy and diminished symptoms for 6 days after the initial treatment. She received another identical treatment at this time and continued to receive them weekly for 8 weeks (Figure 1).

Five months after treatment began, she started receiving additional intramuscular injections (Table 2) to further support symptom relief. Several months later, she also began receiving additional intramuscular injections to take home and self-administer. She reported greater resolution of her symptoms when pyridoxine was included in the injection. With the injection self-administered 1 week after each round of parenteral therapy, she was able to go 2 weeks between treatments with almost no return of symptoms. In 2017, she began to go 3 weeks between treatments with almost no symptoms.

She tolerated all the treatments well except for one visit when the administration of the vitamin and mineral mix led to an episode of hypotension, muscle spasticity, and inability to move or speak for 20 minutes. She had recently initiated isosorbide dinitrate therapy for angina pectoris. Isosorbide dinitrate forms nitric oxide, leading to vasodilation and increased blood flow. It is unclear why this episode was triggered, but the stacked vasodilatory effects of magnesium from the vitamin/mineral mix and nitric oxide from isosorbide dinitrate may have been the cause. The magnesium dose was decreased from 3 mL to 1 mL after this incident, with no further episodes.

Follow-up and Outcomes

At this time, the patient can care for herself and engage in activities of daily living. She receives parenteral therapy every 3 to 4 weeks, has discontinued the intramuscular injections, and reports that between office visits she experiences minimal to no symptoms of dyskinesia.

The patient shared her perspective:

Parenteral vitamin and mineral therapy has been like a miracle drug for me and has significantly improved my quality of life. Without [it], I present as if I have cerebral palsy and Parkinson [disease] along with strokelike speech, all simultaneously, though I do not have any of those conditions. Although the parenteral therapy is not curative, it is keeping the movement disorder under control and provides an almost-instant relief when symptoms are flaring. At my worst times it has felt like life was being infused back into my body when getting a round of treatment. The transformation is incredible: A true Jekyll-and-Hyde type of experience. Of the 16 years I have been living with this disorder, it has only been the last few years that my quality of life has improved, thanks largely to parenteral therapy. I am grateful to have found this.

DISCUSSION

Research on animal models of PKD is consistent with the theory of hyperexcitability in the basal ganglia as a cause of symptoms. Hamster models of PKD have dopaminergic overactivity in the striatum, and both glutamate and dopamine-receptor antagonists reduce symptoms.^8,9 This increase in dopamine may be mediated by nitric oxide, which enhances striatal dopamine release and is synthesized by the enzyme nitric oxide synthase. Nitric oxide synthase inhibitors reduced the severity of dystonia in animal models of PKD for several hours after administration.⁹ There is also a link between  nitric oxide and glutamic acid decarboxylase (GAD); autoantibodies to the GAD enzyme are involved in cerebellar ataxia. The administration of these antibodies to animals increased excitability of motor neurons and reduced the production of nitric oxide.^10,11 The bilateral injection of the GAD enzyme into the subthalamus of patients with advanced Parkinson disease resulted in a reduction of symptoms over 6 months, suggesting that a deficiency of GAD plays a role in some parkinsonian symptoms.¹²

Lack of cerebral blood flow may also contribute to episodes of PKD. One theory is that vascular insufficiency may lead to hypoxic episodes in the basal ganglia, leading to increased production of excitatory amino acids such as glutamate, causing neuronal hyperexcitability. There are cases of PKD secondary to vascular insufficiency in which no structural abnormalities were found on brain imaging, although hypoxia was noted.¹³ 

This theory about reduced blood flow is supported by the induced episode of PKD in the patient when she was given parenteral treatment after recently initiating isosorbide dinitrate therapy for angina. The administered parenteral treatment included magnesium sulfate, which has been shown to modulate the function of acetylcholine receptors.¹⁴ Acetylcholine can activate nitric oxide synthase, increasing nitric oxide concentrations and contributing to vasodilation.¹⁵ Isosorbide dinitrate also forms nitric oxide, and the combined effects of it and magnesium sulfate may have decreased blood pressure, leading to hypoxia in the basal ganglia and a subsequent episode of PKD.

Genetic testing in this patient seemed to support the role of glutamate and GAD in her symptoms of PKD. This patient’s genetic testing revealed a GAD1 mutation. GAD catalyzes the conversion of glutamate to g-aminobutyric acid, requiring pyridoxal 5¢-phosphate (vitamin B₅) as a cofactor. This genetic polymorphism could have allowed glutamate to accumulate, contributing to PKD attacks. The patient was also found to have a MTHFR polymorphism, reducing the ability to convert precursors to active folate, as well as an NBPF3 polymorphism, reducing use of pyridoxine_.¹⁶ Vitamin and mineral therapy was chosen to promote enzyme-cofactor binding and restore the rate of these reactions.¹⁷ To the best of our knowledge, no research exists on parenteral therapy with vitamins and minerals in paroxysmal dyskinesia.

Limitations of this case report include the short duration of action of the treatments, the limited research on the interventions, and the challenges associated with making this diagnosis. The patient’s diagnosis of PKD was complicated by a diagnosis of CFS, confounding both symptom presentation and treatment response (Table 3). Diagnostic guidelines, published 2 years after this patient’s diagnosis, bring her diagnosis into question.¹⁸ The parenteral vitamin and mineral treatment has little research, and these treatments decreased the patient’s symptoms for only days to weeks. In this case, the patient experienced near-resolution of her symptoms with periodic parenteral therapy, and with 1 minor treatment-related episode of PKD symptoms.  Because effective treatments for movement disorders are multidisciplinary, parenteral therapy may be appropriate as adjunctive therapy in some patients.¹⁹

CONCLUSION

This case suggests that parenteral vitamin and mineral administration may be safe in some patients with paroxysmal dyskinesia, although caution must be taken to avoid adverse interactions with medications.

Disclosure Statement

The author(s) have no conflicts of interest to disclose.

Acknowledgments

Kathleen Louden, ELS, of Louden Health Communications performed a primary copy edit.

How to Cite this Article

Bruton A, Fuller L. Paroxysmal kinesigenic dyskinesia symptoms markedly reduced with parenteral vitamins and minerals: A case report. Perm J 2019;23:19.036. DOI: https://doi.org/10.7812/TPP/19.036

Author Affiliations

¹ Helfgott Research Institute at Natural University of Natural Medicine, Portland, OR

² Natural University of Natural Medicine, Portland, OR

³ Oregon Health and Science University, Portland

⁴ University of Western States, Portland, OR

Corresponding Author

Alisha Bruton ()

References

1. Erro R, Sheerin U-M, Bhatia KP. Paroxysmal dyskinesias revisited: A review of 500 genetically proven cases and a new classification. Mov Disord 2014 Aug;29(9):1108-16. DOI: https://doi.org/10.1002/mds.25933.
 2. Gardiner AR, Jaffer F, Dale RC, et al. The clinical and genetic heterogeneity of paroxysmal dyskinesias. Brain 2015;138(12):3567-80. DOI: https://doi.org/10.1093/brain/awv310.
 3. Lotze T, Jankovic J. Paroxysmal kinesigenic dyskinesias. Semin Pediatr Neurol 2003 Mar;10(1):68-79. DOI: https://doi.org/10.1016/S1071-9091(02)00012-8.
 4. Demirkiran M, Jankovic J. Paroxysmal dyskinesias: Clinical features and classification. Ann Neurol 1995 Oct;38(4):571-9. DOI: https://doi.org/10.1002/ana.410380405.
 5. Mehta SH, Morgan JC, Sethi KD. Paroxysmal dyskinesias. Curr Treat Options Neurol 2009 May;11(3):170-8.
 6. Chen W-J, Lin Y, Xiong Z-Q, et al. Exome sequencing identifies truncating mutations in PRRT2 that cause paroxysmal kinesigenic dyskinesia. Nat Genet 2011 Nov 20;43(12):1252-5. DOI: https://doi.org/10.1038/ng.1008.
 7. Riley DS, Barber MS, Kienle GS, et al. CARE guidelines for case reports: Explanation and elaboration document. J Clin Epidemiol 2017 Sep;89:218-35. DOI: https://doi.org/10.1016/j.jclinepi.2017.04.026.
 8. Rehders JH, Löscher W, Richter A. Evidence for striatal dopaminergic overactivity in paroxysmal dystonia indicated by microinjections in a genetic rodent model. Neuroscience 2000 Sep;97(2):267-77. DOI: https://doi.org/10.1016/S0306-4522(00)00073-7.
 9. Richter A, Löschmann PA, Löscher W. Antidystonic efficacy of nitric oxide synthase inhibitors in a rodent model of primary paroxysmal dystonia. Br J Pharmacol 2000 Nov;131(5):921-6. DOI: https://doi.org/10.1038/sj.bjp.0703609.
 10. Mitoma H, Manto M, Hampe CS. Pathogenic roles of glutamic acid decarboxylase 65 autoantibodies in cerebellar ataxias. J Immunol Res 2017;2017:2913297. DOI: https://doi.org/10.1155/2017/2913297.
 11. Manto MU, Hampe CS, Rogemond V, Honnorat J. Respective implications of glutamate decarboxylase antibodies in stiff person syndrome and cerebellar ataxia. Orphanet J Rare Dis 2011;6:3. DOI: https://doi.org/10.1186/1750-1172-6-3.
 12. LeWitt PA, Rezai AR, Leehey MA, et al. AAV2-GAD gene therapy for advanced Parkinson’s disease: A double-blind, sham-surgery controlled, randomised trial. Lancet Neurol 2011 Apr 1;10(4):309-19. DOI: https://doi.org/10.1016/S1474-4422(11)70039-4.
 13. Perlmutter JS, Raichle ME. Pure hemidystonia with basal ganglion abnormalities on positron emission tomography. Ann Neurol 1984 Mar;15(3):228-33. DOI: https://doi.org/10.1002/ana.410150303.
 14. Grassi F, Degasperi V. Modulation of fetal and adult acetylcholine receptors by Ca2+ and Mg2+ at developing mouse end-plates. Pflugers Arch 2000 Sep;440(5):704-9.
 15. Kellogg DL Jr, Zhao JL, Coey U, Green JV. Acetylcholine-induced vasodilation is mediated by nitric oxide and prostaglandins in human skin. J Appl Physiol 2005 Feb 1;98(2):629-32. DOI: https://doi.org/10.1152/japplphysiol.00728.2004.
 16. Tanaka T, Scheet P, Giusti B, et al. Genome-wide association study of vitamin B6, vitamin B12, folate, and homocysteine blood concentrations. Am J Hum Genet 2009 Apr 10;84(4):477-82. DOI: https://doi.org/10.1016/j.ajhg.2009.02.011.
 17. Ames BN, Elson-Schwab I, Silver EA. High-dose vitamin therapy stimulates variant enzymes with decreased coenzyme binding affinity (increased K[m]): Relevance to genetic disease and polymorphisms. Am J Clin Nutr 2002 Apr;75(4):616-58. DOI: https://doi.org/10.1093/ajcn/75.4.616.
 18. Bruno MK, Hallett M, Gwinn-Hardy K, et al. Clinical evaluation of idiopathic paroxysmal kinesigenic dyskinesia: New diagnostic criteria. Neurology 2004 Dec 28;63(12):2280-87. DOI: https://doi.org/10.1212/01.WNL.0000147298.05983.50.
 19. Schwingenschuh P, Pont-Sunyer C, Surtees R, Edwards MJ, Bhatia KP. Psychogenic movement disorders in children: A report of 15 cases and a review of the literature. Mov Disord 2008 Oct 27;23(13):1882-8. DOI: https://doi.org/10.1002/mds.22280.

Keywords: hyperkinetic disorders, movement disorders, parenteral vitamins and minerals, paroxysmal kinesigenic dyskinesia, PKD